CXCL-CXCR1/2-IN-1

SKU: orb2283846

Description

CXCL-CXCR1/2-IN-1 is a potent, orally bioavailable small molecule inhibitor targeting the ELR+ chemokine signaling axis. It demonstrates anticancer and anti-angiogenic effects in preclinical models, making it a valuable tool for investigating cancer biology, tumor angiogenesis, and related cardiovascular pathologies in both in vitro and in vivo studies.

Research Area

Cell Biology, Immunology & Inflammation, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 2415653-55-1
• MW: 383.21
• Purity: 99.40% (May vary between batches)
• Formula: C₁₄H₈Cl₂N₄O₃S
• SMILES: O=C(NC1=CC(Cl)=CC(Cl)=C1)NC2=NC3=C(S2)C=C([N+]([O-])=O)C=C3
• Target: CXCR
• Solubility: DMSO:2 mg/mL (5.22 mM)

Bioactivity

• In Vivo:
  CXCL-CXCR1/2-IN-1 (1 μM; 48h; Female NOD SCID mice injected with 786 RCC cells) reduces the metastatic area in zebrafish embryos injected with A498 cells. CXCL-CXCR1/2-IN-1 (100 mg/kg; oral gavage; twice a day; for 28 days) inhibits tumor growth in mice.
  Read more...
• In Vitro:
  CXCL-CXCR1/2-IN-1 (compound 10; 1-2.5 μM; 24-48h; A498 cells) showed reduced ERK and AKT phosphorylation in A498 cells. CXCL-CXCR1/2-IN-1 also can inhibit the secretion of CXCL1, CXCL5, and CXCL8, which are representative pro-angiogenic ELR+CXCL cytokines.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CXCLCXCR1/2IN1, CXCR

Compound Identifiers

PubChem CID

146487189